What is SUPN's market cap?

$1.64B, based on the Nov 4 close of $28.21.

Does Supernus pay a dividend?

Yes. The latest regular dividend was $8.13 per share (ex-date Nov 3), an annualised yield of 28.82%.

How much of SUPN is sold short?

4.0M shares, 7.3% of float, as of Oct 15, 2026.

What sector is SUPN in?

Healthcare, in the Pharmaceuticals industry.

NASDAQ · SUPNHealthcarePharmaceuticals

Supernus, Inc. Common Stock (SUPN)

$28.21+0.21%

Close Nov 4, 2026 · split-adjusted

Nov 4, 2026$28.21▼ 50.51% in range

Nov 4, 2025Low $28.15 · High $57.00Nov 4, 2026

What changed · written from our data

As of Nov 4, 2026

Supernus closed at $28.21 on Nov 4, up 0.21%, within 0.2% of its 52-week closing low. Volume of 6.6M shares was 4.26× its 20-day average (well above normal).

Split-adjusted performance: -34.1% over one month, -45.2% over six months.

In the quarter ended Sep 30, 2026, revenue was $226.77M, up 18.0% from a year earlier, with a net margin of 9.2%.

Short interest was 4.0M shares at the Oct 15 settlement, down 18.9% from the prior report (7.3% of float, 4.9 days to cover).

Market cap$1.64B58.2M shares

Revenue · quarter$226.8M+18.0% YoY

Diluted EPS$0.35—

P/E · TTM—P/S 1.9×

Net margin9.2%Gross 88.1%

Dividend yield28.82%$8.13 last paid

52-week range28.15 – 57.00−50.5% from high

Volume6.6M4.26× 20-day avg

Volatility · 60d86.1%Annualised

Short % of float7.3%4.9 days to cover

Net cash$359.5MCash $359.5M

Next earnings—Not scheduled

Split-adjusted performance

1W −31.3%1M −34.1%3M −39.7%6M −45.2%YTD −43.2%1Y —3Y +19.4%5Y −3.9%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum29

Revenue growth65

Net margin78

Value (low P/E)—

Size77

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →

Shares short4.0M−18.9% vs prior

Days to cover4.9Settled Oct 15

% of float7.3%

Short vol. 10d63.1%of daily volume

Closest peers by size in Pharmaceuticals

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
SUPNSupernus	$28.21	+0.21%	−45.2%	+18.0%	9.2%	—	$1.64B
ANIPANI Pharmaceuticals	$71.65	−0.87%	−14.8%	+25.9%	8.6%	16.5	$1.65B	Compare
KLRAKailera Therapeutics	$12.80	+1.75%	—	—	—	—	$1.66B	Compare
NUVBNuvation Bio	$4.73	+0.85%	−6.2%	+555.6%	−198.3%	—	$1.66B	Compare
PAHCPhibro Animal Health	$39.43	+4.73%	−32.6%	+4.8%	5.5%	16.1	$1.60B	Compare
QUREuniQure	$23.03	−3.52%	+0.9%	+11.0%	−1387.8%	—	$1.60B	Compare
RAREUltragenyx Pharmaceutical	$17.16	+3.19%	−33.8%	+28.1%	−43.0%	—	$1.69B	Compare
OCULOcular Therapeutix	$7.14	+4.69%	−26.5%	+0.1%	−584.5%	—	$1.57B	Compare
NRIXNurix Therapeutics	$15.95	−38.23%	−5.5%	+8426.3%	81.7%	5.9	$1.74B	Compare

News about Supernus

All news →

Supernus Pharmaceuticals (SUPN) Beats Q3 Earnings and Revenue EstimatesZacks Investment Research · 6d ago▼ Negative Supernus Announces Orphan Drug Exclusivity for ONAPGO™ (apomorphine HCl)GlobeNewswire Inc. · Oct 21, 2026▲ Positive Why Supernus Pharmaceuticals Stock Topped the Market TodayThe Motley Fool · Aug 3, 2026▲ Positive Halper Sadeh LLC is Investigating Whether SUPN, ITGR, BOW are Obtaining Fair Deals for their ShareholdersGlobeNewswire Inc. · Aug 3, 2026▼ Negative Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care ConferenceGlobeNewswire Inc. · May 6, 2026▲ Positive

Quick answers

What does Supernus do?: Supernus Inc is a diversified biopharmaceutical company focused on developing and commercializing treatments for patients living with central nervous system (CNS) diseases. The company's commercial portfolio includes approved treatments designed to support individuals navigating opioid use disorder (OUD), attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's disease (PD) for those receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea.
What is SUPN's market cap?: $1.64B, based on the Nov 4 close of $28.21.
Does Supernus pay a dividend?: Yes. The latest regular dividend was $8.13 per share (ex-date Nov 3), an annualised yield of 28.82%.
How much of SUPN is sold short?: 4.0M shares, 7.3% of float, as of Oct 15, 2026.
What sector is SUPN in?: Healthcare, in the Pharmaceuticals industry.

About Supernus

Supernus Inc is a diversified biopharmaceutical company focused on developing and commercializing treatments for patients living with central nervous system (CNS) diseases. The company's commercial portfolio includes approved treatments designed to support individuals navigating opioid use disorder (OUD), attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's disease (PD) for those receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea.

HQ: Rockville, MD778 employeesListed May 1, 2012supernus.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology